
Laverock names CEO ahead of Series A; GH Research hires J&J depression-drug trial lead; TreeFrog taps former bluebird bio CFO
Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: NeoPhore prepares for its first clinical trial, Laverock builds a team for its next financing and GH Research adds late-stage depression expertise.
Laverock Therapeutics: New leadership for a planned Series A. The London biotech named Parker Moss CEO and Paul J. Sekhri executive chair on November 16. Moss previously led corporate development at Exscientia through its acquisition by Recursion. Sekhri chaired Longboard Pharmaceuticals through its sale to Lundbeck. Founder CEO David Venables will step down December 31. The preclinical company expects to select a candidate from its CAR-T programs in the first half of 2027 and plans a Series A that year.
GH Research: Trial leader for J&J’s blockbuster joins ahead of pivotal studies. Dublin-based GH Research appointed Vanina Popova chief development officer on November 13. At Johnson & Johnson, she led TRANSFORM-2, a pivotal Phase 3 trial of the depression drug Spravato. Popova will oversee development of GH001, GH Research’s inhaled mebufotenin treatment. After a Phase 2b study in treatment-resistant depression, the company expects an FDA end-of-Phase 2 meeting in the first quarter of 2027 before starting a pivotal program; it targets a separate postpartum depression program for the second half of the year.
TreeFrog Therapeutics: Former bluebird bio CFO joins before a clinical filing. The Bordeaux biotech appointed James Sterling chief financial officer, effective November 1. Sterling previously held the same role at bluebird bio (now known as Genetix Biotherapeutics) and Renalytix. At TreeFrog, he will oversee finance, investor relations and corporate development. TreeFrog’s lead cell therapy program for Parkinson’s disease remains preclinical, with a first-in-human clinical trial application targeted for 2027.
NeoPhore: An investor takes the lead before the first trial. The U.K.-based biotech appointed Marianne Bjordal CEO and promoted Judit Molnar to chief development officer on November 13. Bjordal, a general partner at investment firm 3B Future Health Fund, has served on NeoPhore’s board since 2021. Bjordal succeeds Michael Shih, who left the company’s board in May. NeoPhore has not disclosed the circumstances or timing of his departure as CEO. Molnar joined in 2025 after clinical and medical leadership roles at GSK, Galapagos and BenevolentAI. They will guide an oral DNA mismatch repair inhibitor toward NeoPhore’s first clinical trial, planned for 2027 in metastatic colorectal cancer.
Oncorena: A finance hire frees its business chief to focus on deals. The Swedish company appointed Mikael Engblom CFO on November 16. He takes over from Pål Falck, who will focus on his chief business officer role. Engblom previously served as CFO at Vitrolife and BICO Group. The hire also reunites him with Åsa Hillsten, Oncorena’s investor relations and communications adviser since March: the two worked together as advisers to BICO in 2022. Their established working relationship brings finance and investor relations experience together as Oncorena develops ONC175 for metastatic kidney cancer in the clinic.

